QSAM Biosciences Inc. announced the addition of the Ellis Fischel Cancer Center at the University of Missouri School of Medicine as an upcoming clinical trial site to soon begin enrolling participants into the Phase 1 study evaluating CycloSam for participants with multiple types of bone cancer that either originated in or has metastasized to the bone. The Ellis Fischel Cancer Center is accredited as an Academic Comprehensive Cancer Program by the Commission on Cancer, an American College of Surgeons quality program. Ellis Fischel is QSAM's third clinical trial site to be approved for this study which is currently recruiting participants in New Jersey and Texas.

QSAM's study is a multiple center, open label, dose escalation clinical trial intended to determine the maximum tolerated dose of CycloSam in participants, and also assess early efficacy signals. Participants with bone cancer that has metastasized from the breast, lungs, prostate or other organs, as well as participants with cancer that has originated in the bone such as osteosarcoma and Ewing's Sarcoma – diseases that mostly affect children and young adults -- are also eligible subject to the trial's inclusion and exclusion criteria. Adults with bone cancer that has migrated or metastasized from the breast, lung or prostate is common and frequently fatal.

QSAM is dedicated to developing its Cyclosam product for this important population, and participants with any of these bone cancer types are eligible for this clinical trial. Osteosarcoma, while still a rare pediatric disease, is the most common form of bone cancer in children and young adults (ages 15-39) with primary high-grade bone malignancy, and Ewing's Sarcoma bone cancer is the second most common form of bone cancer in children. According to the Cancer Facts & Figures 2021 produced by the American Cancer Society there are about 400,000 new cases of malignant bone metastasis and 3,610 new cases of primary bone cancer diagnosed in the United States each year.